Theriva Biologics Advances Oncology Pipeline with VCN-01

Theriva Biologics, Inc. ( (TOVX) ) has released its Q3 earnings. Here is a breakdown of the information Theriva Biologics, Inc. presented to its investors.

Theriva Biologics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for cancer and related diseases, with a particular emphasis on oncolytic adenoviruses designed to enhance cancer treatment efficacy.

In its latest earnings report, Theriva Biologics highlighted significant advancements in its oncology pipeline, particularly with its lead candidate VCN-01, which showed promising results in a Phase 2b trial for metastatic pancreatic ductal adenocarcinoma (PDAC). The company also presented preclinical data for VCN-12, a next-generation oncolytic virus, at a major medical congress.

The company reported a decrease in general and administrative expenses to $1.9 million, and research and development expenses slightly decreased to $2.6 million. Theriva’s cash position improved to $15.5 million following recent capital raises, extending its cash runway into the first quarter of 2027. The VIRAGE Phase 2b trial of VCN-01 demonstrated improved overall survival and progression-free survival in PDAC patients, supporting plans for a Phase 3 trial.

Theriva’s strategic focus includes advancing regulatory discussions for VCN-01 in both PDAC and retinoblastoma, alongside ongoing preclinical studies for VCN-12. The company is well-positioned to continue its clinical and regulatory strategies, although additional funding will be necessary for new clinical trials.

Looking ahead, Theriva Biologics aims to leverage its strengthened financial position to further its clinical development programs and explore potential partnerships, with a focus on achieving regulatory milestones and expanding its innovative oncology pipeline.